In the News

Can you afford a long life? Americans are living longer and longer, and Managing Director Dave Gilreath says that most investment strategies are playing it too safe when it comes to generating enough income for those extra years.

Read more +

The market has delivered a parade of new highs for major indexes in 2024, but investors may be wondering whether it’s time to cash out before the market declines. Managing Director Dave Gilreath is here to share 9 reasons to believe that the market will perform well for the rest of 2024 and at least early into 2025. Read on in his latest Medical Economics article.

Read more +

Volatility gives investors the heebie jeebies for fear of damaging stock portfolios, but volatility isn’t actually the problem—investors’ reaction to volatility is. Managing Director Dave Gilreath talks about how volatility is widely misunderstood, as well as what volatility actually is and isn’t in his latest article for Medical Economics.

Read more +

After a couple of lower-performing years, the healthcare market sector has recovered over the past six months with the potential to continue improving. With this upturn, Managing Director Dave Gilreath shares six healthcare stocks to consider in his latest article for CNBC.

Read more +

Many advisors today seem to assume that lower federal funds rates will be a magic solution for the market. But just how much of a positive impact should really be expected, and for how long? Managing Director Dave Gilreath shares his thoughts in his latest Financial Advisor article.

Read more +

As of April, the S&P 500 has hit 22 new highs this year. But when should we expect the market to start to descend? Managing Director Dave Gilreath says in his latest Medical Economics article that, while we can’t exactly predict when the next downturn will be, we can look back through market history to get a sense of historical patterns that might repeat.

Read more +

Typically, with an upswing in the market also comes an increase in inflation. But right now, we’re experiencing a decrease in inflation. Why? Economic productivity is a likely candidate, according to Managing Director Dave Gilreath in his latest Medical Economics article.

Read more +

Elevated bond yields have advisors thinking about adding more bonds into their portfolios. And that certainly is an option, but according to Managing Director Dave Gilreath and Senior Portfolio Manager JR Humphreys, so is adding preferred stocks instead, which are experiencing their own growth spurt.

Read more +

What market sectors do you think will grow in 2024? Managing Director Dave Gilreath shares his thoughts in his latest article for Medical Economics.

Read more +

American investors have long been investing in Chinese stocks, despite the fact that they haven’t typically produced positive returns. Managing Director Dave Gilreath dives into this investing phenomenon by assessing the current risks of investing in Chinese stocks.

Read more +

The past four years have been filled with twists and turns on the economic rollercoaster, but a return to normalcy seems to be on the horizon. However, some advisors and investors are still feeling cautious. Read on for Managing Director Dave Gilreath‘s take.

Read more +

Utilities may not be the sexiest stock to own, but they make up for it with their potentially reliable dividends. Managing Partner Dave Gilreath discusses this and more in his latest Financial Advisor article.

Read more +

In his latest Medical Economics article, Managing Partner Dave Gilreath posits that similarities to Newton’s universal law of gravitation can be seen in the stock market with the rise and fall of stock sectors.

Read more +

Sheaff Brock received incredible news in the last half of 2023! Want to know what it was? Benzinga wrote all about it in their latest article.

Read more +

During times of geopolitical conflict, it’s natural that investors may think about defense stocks. In his latest CNBC article, Managing Director Dave Gilreath analyzes a variety of defense companies and stocks for investors to consider.

Read more +

Investing in real estate can possibly result in long-term gain, but at what price? Sheaff Brock’s Managing Partner Dave Gilreath breaks down indirect ways to invest in real estate in his latest Medical Economics article for those looking to dive in.

Read more +

Have you heard of Infectious Doomsday Syndrome (IDS)? Learn how it may be impacting your investments in a recent ThinkAdvisor article by Sheaff Brock’s Managing Partner Dave Gilreath.

Read more +

In Managing Director Dave Gilreath’s latest article with Medical Economics, he considers key distinctions between stocks and bonds and details why discipline and patience are critical for successful stock investing.

Read more +

After more than half a year of doomsday forecasts for the 2023 stock market, Managing Director Dave Gilreath says it may turn out to be the terrible financial year that wasn’t. In this Medical Economics article, he looks back at the year so far and analyzes how the market is doing and where it may go next.

Read more +

2023 has brought some fears surrounding REITs due to rising interest rates pushing up the costs of financing property purchases. However, these fears have turned out to be overblown as the Federal Reserve’s interest rate-hiking cycle is winding down.

Read more +

Listen to Managing Directors Dave Gilreath and Ron Brock on “The Portfolio Playbook” podcast, where they discuss the process of building their own registered investment advisory business and share innovative company growth strategies for other RIAs.

Listen to the podcast +

Managing Director Dave Gilreath explores the building materials sectors and whether there is potential growth to be had there, particularly as the market shifts from a bear market to an embryonic bull market.

Read more +

Managing Directors Dave Gilreath and Ron Brock sit down for an interview with Rick Rosenthal, Director of North American Derivative Sales at Cboe Global Markets, to reflect on the first anniversary of their two ETFs at Innovative Portfolios, Sheaff Brock’s affiliate company.

Watch the interview +

As Managing Director Dave Gilreath mentions in this month’s Medical Economics article, demand for manufacturing and construction materials is increasing, signaling distinct growth potential for this small but important sector.

Read more +